Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12R
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
therascreen® KRAS RGQ PCR Kit (5)
therascreen® KRAS RGQ PCR Kit (5)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G12R
Colon Cancer
KRAS G12R
Colon Cancer
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
KRAS G12R
Colorectal Cancer
KRAS G12R
Colorectal Cancer
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
KRAS G12R
Pancreatic Adenocarcinoma
KRAS G12R
Pancreatic Adenocarcinoma
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
KRAS G12R
Pancreatic Cancer
KRAS G12R
Pancreatic Cancer
cobimetinib
Sensitive: C3 – Early Trials
cobimetinib
Sensitive
:
C3
cobimetinib
Sensitive: C3 – Early Trials
cobimetinib
Sensitive
:
C3
KRAS G12R
Hepatocellular Cancer
KRAS G12R
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
KRAS G12R
Non Small Cell Lung Cancer
KRAS G12R
Non Small Cell Lung Cancer
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
gemcitabine + paclitaxel
Sensitive: C3 – Early Trials
gemcitabine + paclitaxel
Sensitive
:
C3
gemcitabine + paclitaxel
Sensitive: C3 – Early Trials
gemcitabine + paclitaxel
Sensitive
:
C3
KRAS G12R
Non Small Cell Lung Cancer
KRAS G12R
Non Small Cell Lung Cancer
regorafenib
Sensitive: C3 – Early Trials
regorafenib
Sensitive
:
C3
regorafenib
Sensitive: C3 – Early Trials
regorafenib
Sensitive
:
C3
KRAS G12R
Gastric Cancer
KRAS G12R
Gastric Cancer
imatinib
Resistant: C4 – Case Studies
imatinib
Resistant
:
C4
imatinib
Resistant: C4 – Case Studies
imatinib
Resistant
:
C4
KRAS G12R
Colorectal Cancer
KRAS G12R
Colorectal Cancer
sunitinib
Resistant: D – Preclinical
sunitinib
Resistant
:
D
sunitinib
Resistant: D – Preclinical
sunitinib
Resistant
:
D
KRAS G12R
Thyroid Gland Carcinoma
KRAS G12R
Thyroid Gland Carcinoma
trametinib + dasatinib
Sensitive: D – Preclinical
trametinib + dasatinib
Sensitive
:
D
trametinib + dasatinib
Sensitive: D – Preclinical
trametinib + dasatinib
Sensitive
:
D
KRAS G12R
Thyroid Gland Carcinoma
KRAS G12R
Thyroid Gland Carcinoma
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
KRAS G12R
Thyroid Gland Carcinoma
KRAS G12R
Thyroid Gland Carcinoma
dasatinib + SCH772984
Sensitive: D – Preclinical
dasatinib + SCH772984
Sensitive
:
D
dasatinib + SCH772984
Sensitive: D – Preclinical
dasatinib + SCH772984
Sensitive
:
D
KRAS G12R
Thyroid Gland Medullary Carcinoma
KRAS G12R
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
RTB101 + RAF265
Sensitive
:
D
RTB101 + RAF265
Sensitive: D – Preclinical
RTB101 + RAF265
Sensitive
:
D
KRAS G12R
Thyroid Gland Carcinoma
KRAS G12R
Thyroid Gland Carcinoma
dasatinib + selumetinib
Sensitive: D – Preclinical
dasatinib + selumetinib
Sensitive
:
D
dasatinib + selumetinib
Sensitive: D – Preclinical
dasatinib + selumetinib
Sensitive
:
D
KRAS G12R
Thyroid Gland Carcinoma
KRAS G12R
Thyroid Gland Carcinoma
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
KRAS G12R
Thyroid Gland Anaplastic Carcinoma
KRAS G12R
Thyroid Gland Anaplastic Carcinoma
GSKJ4
Sensitive: D – Preclinical
GSKJ4
Sensitive
:
D
GSKJ4
Sensitive: D – Preclinical
GSKJ4
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login